For patients with acute myeloid leukemia (AML) receiving intensive chemotherapy, AML-SCORE and PINA-Score help to estimate 1) complete remission and early death rate in patients ≥60 years and 2) probabilities of overall and relapse-free survival in patients with AML with normal karyotype.
SAL Study Alliance Leukemia

Welcome to the webpage of

This webpage contains two online tools to estimate the prognosis in patients with acute myeloid leukemia (AML).

AML-Score calculates the chance of achieving a complete remission (CR) and the risk of early death within 60 days after an intensive induction therapy in patients of 60 years of age or older with previously untreated AML.

The PINA scores can be used to assign previously untreated adult patients with AML of normal karyotype to groups with different overall survival or relapse-free survival.

These scores are based on pre-therapeutic clinical and molecular parameters. The scores herein are calculated according to the underlying algorithms as published [1,4].

Forgot your password?

Please enter the email address by which you registered your user account. Then press "Send password" and your password will immediately be emailed to you. Make sure to spell your email address correctly.
Send password

Return to login form